Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
|
||
Yes___X___
|
No_______
|
|
Indicate by check mark whether the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
|
||
Yes______
|
No___X___
|
|
Indicate by check mark whether the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
|
||
Yes______
|
No___X___
|
|
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule12g3-2(b) under the Securities Exchange Act of 1934.
|
||
Yes______
|
No___X___
|
|
If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):82 N/A
|
(Unaudited)
|
(Audited)
|
|||||||
June 30,
|
December 31,
|
|||||||
2016
|
2015
|
*
|
||||||
ASSETS
|
(in thousands)
|
|||||||
Current Assets:
|
||||||||
Cash and cash equivalents
|
$
|
168,470
|
$
|
103,911
|
||||
Short term investments - available for sale
|
82,481
|
85,990
|
||||||
Accounts receivable, net
|
366,903
|
409,165
|
||||||
Unbilled revenue
|
190,025
|
173,649
|
||||||
Other receivables
|
39,097
|
30,935
|
||||||
Prepayments and other current assets
|
37,180
|
36,128
|
||||||
Income taxes receivable
|
24,832
|
22,961
|
||||||
Total current assets
|
908,988
|
862,739
|
||||||
Other Assets:
|
||||||||
Property, plant and equipment, net
|
150,987
|
150,218
|
||||||
Goodwill
|
590,428
|
588,434
|
||||||
Non-current other assets
|
13,306
|
11,591
|
||||||
Non-current income taxes receivable
|
10,206
|
11,362
|
||||||
Non-current deferred tax asset
|
18,744
|
26,738
|
||||||
Intangible assets
|
57,581
|
66,127
|
||||||
Total Assets
|
$
|
1,750,240
|
$
|
1,717,209
|
||||
LIABILITIES AND SHAREHOLDERS’ EQUITY
|
||||||||
Current Liabilities:
|
||||||||
Accounts payable
|
$
|
6,123
|
$
|
7,021
|
||||
Payments on account
|
257,514
|
318,697
|
||||||
Other liabilities
|
178,941
|
231,879
|
||||||
Income taxes payable
|
14,337
|
14,203
|
||||||
Total current liabilities
|
456,915
|
571,800
|
||||||
Other Liabilities:
|
||||||||
Non-current bank credit lines and loan facilities
|
348,322
|
348,306
|
||||||
Non-current other liabilities
|
14,309
|
12,224
|
||||||
Non-current government grants
|
959
|
959
|
||||||
Non-current income taxes payable
|
15,655
|
16,180
|
||||||
Non-current deferred tax liability
|
4,111
|
4,644
|
||||||
Shareholders' Equity:
|
||||||||
Ordinary shares, par value 6 euro cents per share; 100,000,000 shares authorized,
|
||||||||
55,459,627 shares issued and outstanding at June 30, 2016 and
|
||||||||
54,958,912 shares issued and outstanding at December 31, 2015
|
4,685
|
4,679
|
||||||
Additional paid‑in capital
|
408,588
|
383,395
|
||||||
Capital redemption reserve
|
715
|
715
|
||||||
Accumulated other comprehensive income
|
(64,000
|
)
|
(61,636
|
)
|
||||
Retained earnings
|
559,981
|
435,943
|
||||||
Total Shareholders' Equity
|
909,969
|
763,096
|
||||||
Total Liabilities and Shareholders' Equity
|
$
|
1,750,240
|
$
|
1,717,209
|
Three Months Ended
|
Six Months Ended
|
|||||||||||||||
June 30,
|
June 30,
|
June 30,
|
June 30,
|
|||||||||||||
2016
|
2015
|
2016
|
2015
|
|||||||||||||
(in thousands except share and per share data)
|
||||||||||||||||
Revenue:
|
||||||||||||||||
Gross revenue
|
$
|
589,647
|
$
|
524,098
|
$
|
1,132,230
|
$
|
1,027,464
|
||||||||
Reimbursable expenses
|
(179,017
|
)
|
(135,441
|
)
|
(321,078
|
)
|
(250,576
|
)
|
||||||||
Net revenue
|
410,630
|
388,657
|
811,152
|
776,888
|
||||||||||||
Costs and expenses:
|
||||||||||||||||
Direct costs
|
237,984
|
224,961
|
466,587
|
453,039
|
||||||||||||
Selling, general and administrative expense
|
80,168
|
81,321
|
160,957
|
160,875
|
||||||||||||
Depreciation and amortization
|
14,457
|
14,244
|
29,577
|
28,169
|
||||||||||||
Restructuring
|
4,094
|
-
|
4,094
|
-
|
||||||||||||
Total costs and expenses
|
336,703
|
320,526
|
661,215
|
642,083
|
||||||||||||
Income from operations
|
73,927
|
68,131
|
149,937
|
134,805
|
||||||||||||
Interest income
|
359
|
219
|
693
|
495
|
||||||||||||
Interest expense
|
(3,198
|
)
|
(229
|
)
|
(6,413
|
)
|
(508
|
)
|
||||||||
Income before provision for income taxes
|
71,088
|
68,121
|
144,217
|
134,792
|
||||||||||||
Provision for income taxes
|
(10,014
|
)
|
(9,537
|
)
|
(20,179
|
)
|
(20,338
|
)
|
||||||||
Net income
|
$
|
61,074
|
$
|
58,584
|
$
|
124,038
|
$
|
114,454
|
||||||||
Net income per Ordinary Share:
|
||||||||||||||||
Basic
|
$
|
1.10
|
$
|
0.97
|
$
|
2.25
|
$
|
1.90
|
||||||||
Diluted
|
$
|
1.08
|
$
|
0.95
|
$
|
2.20
|
$
|
1.85
|
||||||||
Weighted average number of Ordinary Shares outstanding:
|
||||||||||||||||
Basic
|
55,318,923
|
60,244,982
|
55,164,971
|
60,263,021
|
||||||||||||
Diluted
|
56,580,799
|
61,801,687
|
56,427,516
|
61,849,326
|
Six Months Ended
|
||||||||
June 30,
|
June 30,
|
|||||||
2016
|
2015
|
|||||||
(in thousands)
|
||||||||
Cash flows from operating activities:
|
||||||||
Net income
|
$
|
124,038
|
$
|
114,454
|
||||
Adjustments to reconcile net income to net cash provided by operating activities:
|
||||||||
Loss on disposal of property, plant and equipment
|
27
|
4
|
||||||
Depreciation expense
|
20,699
|
19,672
|
||||||
Amortization of intangibles
|
8,878
|
8,497
|
||||||
Amortization of grants
|
(22
|
)
|
(25
|
)
|
||||
Accrued interest on short term investments
|
(422
|
)
|
-
|
|||||
Realised gain on sale of short term investments
|
(39
|
)
|
-
|
|||||
Share compensation expense
|
20,690
|
15,012
|
||||||
Amortization of gain on interest rate hedge
|
(458
|
)
|
-
|
|||||
Amortization of financing costs
|
276
|
-
|
||||||
Deferred taxes
|
7,469
|
2,126
|
||||||
Changes in assets and liabilities:
|
||||||||
Decrease in accounts receivable
|
42,548
|
21,362
|
||||||
Increase in unbilled revenue
|
(15,892
|
)
|
(28,422
|
)
|
||||
Increase in other receivables
|
(8,305
|
)
|
(4,398
|
)
|
||||
Increase in prepayments and other current assets
|
(1,117
|
)
|
(9,032
|
)
|
||||
Increase in other non-current assets
|
(1,505
|
)
|
(722
|
)
|
||||
Decrease in payments on account
|
(61,187
|
)
|
(15,747
|
)
|
||||
Decrease in other current liabilities
|
(48,168
|
)
|
(40,508
|
)
|
||||
Increase in other non-current liabilities
|
2,108
|
2,146
|
||||||
(Decrease)/increase in income taxes payable
|
(763
|
)
|
1,980
|
|||||
(Decrease)/increase in accounts payable
|
(868
|
)
|
2,792
|
|||||
Change in deferred tax liability
|
(4,233
|
)
|
-
|
|||||
Net cash provided by operating activities
|
83,754
|
89,191
|
||||||
Cash flows from investing activities:
|
||||||||
Purchase of property, plant and equipment
|
(19,893
|
)
|
(24,088
|
)
|
||||
Purchase of subsidiary undertakings
|
(1,613
|
)
|
(103,139
|
)
|
||||
Purchase of short term investments
|
(10,969
|
)
|
(636
|
)
|
||||
Sale of short term investments |
15,441
|
13,184
|
||||||
Net cash used in investing activities
|
(17,034
|
)
|
(114,679
|
)
|
||||
Cash flows from financing activities:
|
||||||||
Proceeds from exercise of share options & restricted share units
|
2,180
|
11,024
|
||||||
Share issuance costs
|
(9
|
)
|
(4
|
)
|
||||
Tax benefit from the exercise of share options
|
2,338
|
2,463
|
||||||
Repurchase of ordinary shares
|
-
|
(57,892
|
)
|
|||||
Share repurchase costs
|
-
|
(289
|
)
|
|||||
Drawdown of bank credit lines and loan facilities
|
20,000
|
60,000
|
||||||
Repayment of bank credit lines and loan facilities
|
(20,000 | ) | - | |||||
Financing costs
|
(6,541
|
)
|
-
|
|||||
Net cash used by financing activities
|
(2,032
|
)
|
15,302
|
|||||
Effect of exchange rate movements on cash
|
(129
|
)
|
(1,245
|
)
|
||||
Net increase/(decrease) in cash and cash equivalents
|
64,559
|
(11,431
|
)
|
|||||
Cash and cash equivalents at beginning of period
|
103,911
|
118,900
|
||||||
Cash and cash equivalents at end of period
|
$
|
168,470
|
$
|
107,469
|
Shares
|
Amount
|
Additional
Paid-in
Capital
|
Capital
Redemption
Reserve
|
Accumulated
Other Comprehensive Income
|
Retained
Earnings
|
Total
|
||||||||||||||||||||||
(dollars in thousands, except share data)
|
||||||||||||||||||||||||||||
Balance at December 31, 2015
|
54,958,912
|
$
|
4,679
|
$
|
383,395
|
$
|
715
|
|
($61,636
|
)
|
$
|
435,943
|
$
|
763,096
|
||||||||||||||
Comprehensive Income:
|
||||||||||||||||||||||||||||
Net income
|
-
|
-
|
-
|
-
|
-
|
124,038
|
124,038
|
|||||||||||||||||||||
Currency translation adjustment
|
-
|
-
|
-
|
-
|
(3,107
|
)
|
-
|
(3,107
|
)
|
|||||||||||||||||||
Currency impact of long term funding
|
-
|
-
|
-
|
-
|
302
|
-
|
302
|
|||||||||||||||||||||
Tax on currency impact of long term funding
|
-
|
-
|
-
|
-
|
397
|
-
|
397
|
|||||||||||||||||||||
Unrealized capital gain – investments
|
-
|
-
|
-
|
-
|
502
|
-
|
502
|
|||||||||||||||||||||
Amortization of interest rate hedge
|
- | - | - | - | (458 | ) | - | (458 | ) | |||||||||||||||||||
Total comprehensive income
|
-
|
-
|
-
|
-
|
(2,364
|
)
|
124,038
|
121,674
|
||||||||||||||||||||
Exercise of share options
|
93,168
|
6
|
2,146
|
-
|
-
|
-
|
2,152
|
|||||||||||||||||||||
Issue of restricted share units
|
407,547
|
-
|
28
|
-
|
-
|
-
|
28
|
|||||||||||||||||||||
Share issuance costs
|
-
|
-
|
(9
|
)
|
-
|
-
|
-
|
(9
|
)
|
|||||||||||||||||||
Non-cash stock compensation expense
|
-
|
-
|
20,690
|
-
|
-
|
-
|
20,690
|
|||||||||||||||||||||
Tax benefit on exercise of options
|
-
|
-
|
2,338
|
-
|
-
|
-
|
2,338
|
|||||||||||||||||||||
Balance at June 30, 2016
|
55,459,627
|
$
|
4,685
|
$
|
408,588
|
$
|
715
|
|
($64,000
|
)
|
$
|
559,981
|
$
|
909,969
|
Six months ended
|
Year ended
|
|||||||
June 30,
|
December 31,
|
|||||||
2016
|
2015
|
|||||||
(in thousands)
|
||||||||
Opening balance
|
$
|
588,434
|
$
|
463,324
|
||||
Current period acquisitions (Note 3)
|
-
|
133,123
|
||||||
Prior period acquisitions (Note 3)
|
5,773
|
4,418
|
||||||
Foreign exchange movement
|
(3,779
|
)
|
(12,431
|
)
|
||||
Closing balance
|
$
|
590,428
|
$
|
588,434
|
December 4,
|
||||
2015
|
||||
(in thousands)
|
||||
Cash
|
$
|
194
|
||
Property, plant and equipment
|
712 | |||
Goodwill*
|
46,812
|
|||
Intangible assets**
|
10,582
|
|||
Accounts receivable
|
12,747
|
|||
Prepayments and other current assets
|
1,329
|
|||
Accounts payable
|
(530
|
)
|
||
Other liabilities
|
(2,459
|
)
|
||
Non-current deferred tax liability
|
(4,233
|
)
|
||
Net assets acquired
|
65,154
|
|||
Cash consideration | 53,681 | |||
Other liabilities assumed | 9,860 | |||
Working capital adjustment
|
1,613
|
|||
Total cash outflows
|
65,154
|
February 27,
|
||||
2015
|
||||
(in thousands)
|
||||
Property, plant and equipment
|
$
|
1,049
|
||
Goodwill*
|
92,084
|
|||
Customer lists
|
22,752
|
|||
Order backlog
|
2,521
|
|||
Accounts receivable
|
5,240
|
|||
Unbilled Revenue
|
4,324
|
|||
Prepayments and other current assets
|
621
|
|||
Accounts payable
|
(749
|
)
|
||
Payments on account
|
(4,186
|
)
|
||
Deferred tax liability
|
(2,171
|
)
|
||
Other liabilities
|
(5,483
|
)
|
||
Net assets acquired
|
$
|
116,002
|
||
Cash consideration
|
$
|
108,717
|
||
Other liabilities assumed**
|
11,283
|
|||
Gross cash outflows
|
120,000
|
|||
Working capital adjustment
|
(3,998
|
)
|
||
Net cash outflows
|
$
|
116,002
|
* | Goodwill represents the acquisition of an established workforce with experience in the provision of strategic payer-validated market access solutions while the acquisition of Complete Healthcare Communications comprises an established workforce with significant communication experience working with medical affairs, commercial and brand development teams within the life science industry. |
** | Payments made at acquisition date of $11.3 million were in respect of certain one-time liabilities which have subsequently been discharged. |
May 7,
|
||||
2014
|
||||
(in thousands)
|
||||
Property, plant and equipment
|
$
|
6,924
|
||
Goodwill*
|
125,627
|
|||
Customer relationships
|
21,400
|
|||
Order backlog
|
7,900
|
|||
Cash and cash equivalents
|
3,484
|
|||
Accounts receivable
|
25,091
|
|||
Unbilled revenue
|
21,154
|
|||
Prepayments and other current assets
|
4,180
|
|||
Non-current assets
|
2,911
|
|||
Accounts payable
|
(9,565
|
)
|
||
Other liabilities
|
(29,782
|
)
|
||
Payments on account
|
(31,094
|
)
|
||
Non-current other liabilities
|
(11,303
|
)
|
||
Loan notes payable**
|
(17,790
|
)
|
||
Net assets acquired
|
$
|
119,137
|
||
Cash consideration
|
$
|
143,500
|
||
Working capital adjustment
|
(1,964
|
)
|
||
141,536
|
||||
Adjustments to cash consideration**
|
(22,399
|
)
|
||
Net purchase consideration
|
$
|
119,137
|
Three Months Ended
|
Six Months Ended
|
|||||||||||||||
June
30,
|
June
30,
|
June
30,
|
June
30,
|
|||||||||||||
2016
|
2015
|
2016
|
2015
|
|||||||||||||
(in thousands)
|
(in thousands)
|
|||||||||||||||
Restructuring charges
|
$
|
4,094
|
-
|
$
|
4,094
|
-
|
||||||||||
Total
|
$
|
4,094
|
|
-
|
$
|
4,094
|
|
-
|
Workforce
reductions
|
||||
(in thousands)
|
||||
Initial restructuring charge recorded
|
$
|
4,094
|
||
Cash payments
|
$
|
(901
|
)
|
|
Foreign exchange movement
|
-
|
|||
Provision at June 30, 2016
|
$
|
3,193
|
Three Months Ended
|
Six Months Ended
|
|||||||||||||||
June 30,
|
June 30,
|
June 30,
|
June 30,
|
|||||||||||||
2016
|
2015
|
2016
|
2015
|
|||||||||||||
|
(In thousands)
|
(In thousands)
|
||||||||||||||
Provision for income taxes before restructuring and other items
|
$
|
10,526
|
$
|
9,537
|
$
|
20,691
|
$
|
20,338
|
||||||||
Tax impact of restructuring and other items
|
(512
|
)
|
-
|
(512
|
)
|
-
|
||||||||||
Provision for income taxes after restructuring and other items
|
$
|
10,014
|
$
|
9,537
|
$
|
20,179
|
$
|
20,338
|
Three Months Ended
|
Six Months Ended
|
|||||||||||||||
June 30,
|
June 30,
|
June 30,
|
June 30,
|
|||||||||||||
2016
|
2015
|
2016
|
2015
|
|||||||||||||
Weighted average number of
ordinary shares outstanding for
basic net income per ordinary share
|
55,318,923
|
60,244,982
|
55,164,971
|
60,263,021
|
||||||||||||
Effect of dilutive share options
outstanding
|
1,261,876
|
1,556,705
|
1,262,545
|
1,586,305
|
||||||||||||
Weighted average number of
ordinary shares outstanding for
diluted net income per ordinary share
|
56,580,799
|
61,801,687
|
56,427,516
|
61,849,326
|
Options
Outstanding
Number of Shares
|
Weighted
Average
Exercise
Price
|
Weighted
Average
Fair Value
|
Weighted
Average
Remaining Contractual
Life
|
|||||||||||||
Outstanding at December 31, 2015
|
1,626,582
|
$
|
34.87
|
$
|
11.94
|
|||||||||||
Granted
|
256,191
|
$
|
69.61
|
$
|
20.10
|
|||||||||||
Exercised
|
(93,168
|
)
|
$
|
23.10
|
$
|
9.35
|
||||||||||
Forfeited
|
(9,765
|
)
|
$
|
22.48
|
$
|
9.57
|
||||||||||
Outstanding at June 30, 2016
|
1,779,840
|
$
|
40.55
|
$
|
13.26
|
4.83
|
||||||||||
Exercisable at June 30, 2016
|
886,188
|
$
|
28.36
|
$
|
10.41
|
3.50
|
Options
Outstanding
Number of Shares
|
Weighted Average Exercise Price
|
Weighted Average Fair Value
|
||||||||||
Non vested outstanding at December 31, 2015
|
968,853
|
$
|
42.14
|
$
|
13.69
|
|||||||
Granted
|
256,191
|
$
|
69.61
|
$
|
20.10
|
|||||||
Vested
|
(324,315
|
)
|
$
|
35.35
|
$
|
12.22
|
||||||
Forfeited
|
(7,077
|
)
|
$
|
21.97
|
$
|
9.52
|
||||||
Non vested outstanding at June 30, 2016
|
893,652
|
$
|
52.64
|
$
|
16.10
|
Six Months Ended
|
||||||||
June 30,
|
June 30,
|
|||||||
2016
|
2015
|
|||||||
Weighted average fair value
|
$
|
20.10
|
$
|
19.75
|
||||
Assumptions:
|
||||||||
Expected volatility
|
30
|
%
|
30
|
%
|
||||
Dividend yield
|
0
|
%
|
0
|
%
|
||||
Risk-free interest rate
|
1.39
|
%
|
1.58
|
%
|
||||
Expected life
|
5 years
|
5 years
|
PSU
Outstanding
Number of
Shares
|
PSU
Weighted
Average
Fair Value
|
PSU
Weighted
Average
Remaining Contractual
Life
|
RSU
Outstanding
Number of
Shares
|
RSU
Weighted
Average
Fair Value
|
RSU
Weighted
Average
Remaining Contractual
Life
|
|||||||||||||||||||
Outstanding at December 31, 2015
|
901,773
|
$
|
48.33
|
1.22
|
1,067,613
|
$
|
48.30
|
1.48
|
||||||||||||||||
Granted
|
247,992
|
$
|
71.58
|
368,889
|
$
|
66.81
|
||||||||||||||||||
Shares vested
|
(253,602
|
)
|
$
|
32.38
|
(153,945
|
)
|
$
|
35.33
|
||||||||||||||||
Forfeited
|
(436
|
)
|
$
|
31.49
|
(57,331
|
)
|
$
|
49.68
|
||||||||||||||||
Outstanding at June 30, 2016
|
895,727
|
$
|
57.78
|
1.42
|
1,225,226
|
$
|
55.44
|
1.65
|
Three Months Ended
|
Six Months Ended
|
|||||||||||||||
June
30,
|
June
30,
|
June
30,
|
June
30,
|
|||||||||||||
2016
|
2015
|
2016
|
2015
|
|||||||||||||
(in thousands)
|
(in thousands)
|
|||||||||||||||
Direct costs
|
$
|
5,790
|
$
|
4,636
|
$
|
11,075
|
$
|
7,966
|
||||||||
Selling, general and administrative
|
5,309
|
4,333
|
9,615
|
7,046
|
||||||||||||
$
|
11,099
|
$
|
8,969
|
$
|
20,690
|
$
|
15,012
|
Three Months ended
|
Six Months Ended
|
|||||||||||||||
June 30,
|
June 30,
|
June 30,
|
June 30,
|
|||||||||||||
2016
|
2015
|
2016
|
2015
|
|||||||||||||
(in thousands)
|
(in thousands)
|
|||||||||||||||
Ireland
|
$
|
95,653
|
$
|
105,413
|
$
|
196,488
|
$
|
219,503
|
||||||||
Rest of Europe
|
79,436
|
78,540
|
155,078
|
162,628
|
||||||||||||
U.S.
|
193,377
|
164,300
|
377,467
|
314,364
|
||||||||||||
Rest of World
|
42,164
|
40,404
|
82,119
|
80,393
|
||||||||||||
Total
|
$
|
410,630
|
$
|
388,657
|
$
|
811,152
|
$
|
776,888
|
Three Months Ended
|
Six Months Ended
|
|||||||||||||||
June 30,
|
June 30,
|
June 30,
|
June 30,
|
|||||||||||||
2016
|
2015
|
2016
|
2015
|
|||||||||||||
(in thousands)
|
(in thousands)
|
|||||||||||||||
Ireland
|
$
|
54,597
|
$
|
49,436
|
$
|
114,148
|
$
|
97,002
|
||||||||
Rest of Europe
|
4,863
|
3,521
|
8,307
|
10,307
|
||||||||||||
U.S.
|
11,826
|
12,592
|
22,610
|
22,447
|
||||||||||||
Rest of World
|
2,641
|
2,582
|
4,872
|
5,049
|
||||||||||||
Total
|
$
|
73,927
|
$
|
68,131
|
$
|
149,937
|
$
|
134,805
|
Three Months Ended
|
Six Months Ended
|
|||||||||||||||
June 30,
|
June 30,
|
June 30,
|
June 30,
|
|||||||||||||
2016
|
2015
|
2016
|
2015
|
|||||||||||||
(in thousands)
|
(in thousands)
|
|||||||||||||||
Ireland
|
$
|
58,326
|
$
|
49,436
|
$
|
117,877
|
$
|
97,002
|
||||||||
Rest of Europe
|
5,171
|
3,521
|
8,615
|
10,307
|
||||||||||||
U.S.
|
11,826
|
12,592
|
22,610
|
22,447
|
||||||||||||
Rest of World
|
2,698
|
2,582
|
4,929
|
5,049
|
||||||||||||
Total
|
$
|
78,021
|
$
|
68,131
|
$
|
154,031
|
$
|
134,805
|
June 30,
|
December 31,
|
|||||||
2016
|
2015
|
|||||||
(in thousands)
|
||||||||
Ireland
|
$
|
105,892
|
$
|
101,736
|
||||
Rest of Europe
|
7,117
|
7,334
|
||||||
U.S.
|
31,750
|
34,520
|
||||||
Rest of World
|
6,228
|
6,628
|
||||||
Total
|
$
|
150,987
|
$
|
150,218
|
Three Months Ended
|
Six Months Ended
|
|||||||||||||||
June 30,
|
June 30,
|
June 30,
|
June 30,
|
|||||||||||||
2016
|
2015
|
2016
|
2015
|
|||||||||||||
(in thousands)
|
(in thousands)
|
|||||||||||||||
Ireland
|
$
|
6,654
|
$
|
4,915
|
$
|
12,558
|
$
|
9,828
|
||||||||
Rest of Europe
|
1,820
|
1,946
|
3,535
|
4,214
|
||||||||||||
U.S.
|
5,137
|
6,417
|
11,786
|
12,135
|
||||||||||||
Rest of World
|
846
|
966
|
1,698
|
1,992
|
||||||||||||
Total
|
$
|
14,457
|
$
|
14,244
|
$
|
29,577
|
$
|
28,169
|
June 30,
|
December 31,
|
|||||||
2016
|
2015
|
*
|
||||||
(in thousands)
|
||||||||
Ireland
|
$
|
620,924
|
$
|
663,060
|
||||
Rest of Europe
|
421,570
|
343,733
|
||||||
U.S.
|
619,866
|
641,769
|
||||||
Rest of World
|
87,880
|
68,647
|
||||||
Total
|
$
|
1,750,240
|
$
|
1,717,209
|
Three Months Ended
|
||||||||||||
June 30,
2016
|
June 30,
2015
|
2016
to 2015
|
||||||||||
Percentage
|
||||||||||||
Percentage of Net Revenue
|
Increase/
(Decrease)
|
|||||||||||
Net revenue
|
100.0
|
%
|
100.0
|
%
|
5.7
|
%
|
||||||
Costs and expenses:
|
||||||||||||
Direct costs
|
58.0
|
%
|
57.9
|
%
|
5.8
|
%
|
||||||
Selling, general and administrative
|
19.5
|
%
|
20.9
|
%
|
(1.4
|
)%
|
||||||
Depreciation |
2.5
|
%
|
2.5 | % | 7.9 | % | ||||||
Amortization | 1.0 | % | 1.2 | % | (12.5 | )% | ||||||
Restructuring
|
1.0
|
%
|
-
|
%
|
100
|
%
|
||||||
Income from operations
|
18.0
|
%
|
17.5
|
%
|
8.5
|
%
|
Six Months Ended
|
||||||||||||
June 30,
2016
|
June 30,
2015
|
2016
to 2015
|
||||||||||
Percentage
|
||||||||||||
Percentage of Net Revenue
|
Increase/
(Decrease)
|
|||||||||||
Net revenue
|
100.0
|
%
|
100.0
|
%
|
4.4
|
%
|
||||||
Costs and expenses:
|
||||||||||||
Direct costs
|
57.5
|
%
|
58.3
|
%
|
3.0
|
%
|
||||||
Selling, general and administrative
|
19.8
|
%
|
20.7
|
%
|
0.1
|
%
|
||||||
Depreciation
|
2.6
|
%
|
2.5
|
%
|
5.2
|
%
|
||||||
Amortization
|
1.1
|
% |
1.1
|
% |
4.5
|
% | ||||||
Restructuring
|
0.5
|
%
|
-
|
100
|
%
|
|||||||
Income from operations
|
18.5
|
%
|
17.4
|
%
|
11.2
|
%
|
|
|
ICON plc
|
|
|
|
|
|
|
|
|
|
/s/ Brendan Brennan | |||
Date: July 26, 2016 | Brendan Brennan | ||
Chief Financial Officer |
Document and Entity Information |
6 Months Ended |
---|---|
Jun. 30, 2016 | |
Document Information [Line Items] | |
Document Type | 6-K |
Amendment Flag | false |
Document Period End Date | Jun. 30, 2016 |
Document Fiscal Year Focus | 2016 |
Document Fiscal Period Focus | Q2 |
Trading Symbol | ICLR |
Entity Registrant Name | ICON PLC |
Entity Central Index Key | 0001060955 |
Current Fiscal Year End Date | --12-31 |
Condensed Consolidated Balance Sheets (Parenthetical) - € / shares |
Jun. 30, 2016 |
Dec. 31, 2015 |
[1] | ||
---|---|---|---|---|---|
Ordinary shares, par value | € 0.06 | € 0.06 | |||
Ordinary shares, shares authorized | 100,000,000 | 100,000,000 | |||
Ordinary shares, shares issued | 55,459,627 | 54,958,912 | |||
Ordinary shares, shares outstanding | 55,459,627 | 54,958,912 | |||
|
Condensed Consolidated Statements of Operations - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Jun. 30, 2016 |
Jun. 30, 2015 |
Jun. 30, 2016 |
Jun. 30, 2015 |
|
Revenue: | ||||
Gross revenue | $ 589,647 | $ 524,098 | $ 1,132,230 | $ 1,027,464 |
Reimbursable expenses | (179,017) | (135,441) | (321,078) | (250,576) |
Net revenue | 410,630 | 388,657 | 811,152 | 776,888 |
Costs and expenses: | ||||
Direct costs | 237,984 | 224,961 | 466,587 | 453,039 |
Selling, general and administrative expense | 80,168 | 81,321 | 160,957 | 160,875 |
Depreciation and amortization | 14,457 | 14,244 | 29,577 | 28,169 |
Restructuring | 4,094 | 4,094 | ||
Total costs and expenses | 336,703 | 320,526 | 661,215 | 642,083 |
Income from operations | 73,927 | 68,131 | 149,937 | 134,805 |
Interest income | 359 | 219 | 693 | 495 |
Interest expense | (3,198) | (229) | (6,413) | (508) |
Income before provision for income taxes | 71,088 | 68,121 | 144,217 | 134,792 |
Provision for income taxes | (10,014) | (9,537) | (20,179) | (20,338) |
Net income | $ 61,074 | $ 58,584 | $ 124,038 | $ 114,454 |
Net income per Ordinary Share: | ||||
Basic | $ 1.10 | $ 0.97 | $ 2.25 | $ 1.90 |
Diluted | $ 1.08 | $ 0.95 | $ 2.20 | $ 1.85 |
Weighted average number of Ordinary Shares outstanding: | ||||
Basic | 55,318,923 | 60,244,982 | 55,164,971 | 60,263,021 |
Diluted | 56,580,799 | 61,801,687 | 56,427,516 | 61,849,326 |
Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands |
6 Months Ended | ||||
---|---|---|---|---|---|
Jun. 30, 2016 |
Jun. 30, 2015 |
||||
Cash flows from operating activities: | |||||
Net income | $ 124,038 | $ 114,454 | |||
Adjustments to reconcile net income to net cash provided by operating activities: | |||||
Loss on disposal of property, plant and equipment | 27 | 4 | |||
Depreciation expense | 20,699 | 19,672 | |||
Amortization of intangibles | 8,878 | 8,497 | |||
Amortization of grants | (22) | (25) | |||
Accrued interest on short term investments | (422) | ||||
Realised gain on sale of short term investments | (39) | ||||
Share compensation expense | 20,690 | 15,012 | |||
Amortization of gain on interest rate hedge | (458) | ||||
Amortization of financing costs | 276 | ||||
Deferred taxes | 7,469 | 2,126 | |||
Changes in assets and liabilities: | |||||
Decrease in accounts receivable | 42,548 | 21,362 | |||
Increase in unbilled revenue | (15,892) | (28,422) | |||
Increase in other receivables | (8,305) | (4,398) | |||
Increase in prepayments and other current assets | (1,117) | (9,032) | |||
Increase in other non-current assets | (1,505) | (722) | |||
Decrease in payments on account | (61,187) | (15,747) | |||
Decrease in other current liabilities | (48,168) | (40,508) | |||
Increase in other non-current liabilities | 2,108 | 2,146 | |||
(Decrease)/increase in income taxes payable | (763) | 1,980 | |||
(Decrease)/increase in accounts payable | (868) | 2,792 | |||
Change in deferred tax liability | (4,233) | ||||
Net cash provided by operating activities | 83,754 | 89,191 | |||
Cash flows from investing activities: | |||||
Purchase of property, plant and equipment | (19,893) | (24,088) | |||
Purchase of subsidiary undertakings | (1,613) | (103,139) | |||
Purchase of short term investments | (10,969) | (636) | |||
Sale of short term investments | 15,441 | 13,184 | |||
Net cash used in investing activities | (17,034) | (114,679) | |||
Cash flows from financing activities: | |||||
Proceeds from exercise of share options & restricted share units | 2,180 | 11,024 | |||
Share issuance costs | (9) | (4) | |||
Tax benefit from the exercise of share options | 2,338 | 2,463 | |||
Repurchase of ordinary shares | (57,892) | ||||
Share repurchase costs | (289) | ||||
Drawdown of bank credit lines and loan facilities | 20,000 | 60,000 | |||
Repayment of bank credit lines and loan facilities | (20,000) | ||||
Financing costs | (6,541) | ||||
Net cash used by financing activities | (2,032) | 15,302 | |||
Effect of exchange rate movements on cash | (129) | (1,245) | |||
Net increase/(decrease) in cash and cash equivalents | 64,559 | (11,431) | |||
Cash and cash equivalents at beginning of period | 103,911 | [1] | 118,900 | ||
Cash and cash equivalents at end of period | $ 168,470 | $ 107,469 | |||
|
Condensed Consolidated Statements of Shareholders' Equity and Comprehensive Income - 6 months ended Jun. 30, 2016 - USD ($) $ in Thousands |
Total |
Ordinary Shares |
Additional Paid-in Capital |
Capital Redemption Reserve |
Accumulated Other Comprehensive Income |
Retained Earnings |
|||
---|---|---|---|---|---|---|---|---|---|
Balance (in shares) at Dec. 31, 2015 | 54,958,912 | [1] | 54,958,912 | ||||||
Balance at Dec. 31, 2015 | $ 763,096 | [1] | $ 4,679 | $ 383,395 | $ 715 | $ (61,636) | $ 435,943 | ||
Comprehensive Income: | |||||||||
Net income | 124,038 | 124,038 | |||||||
Currency translation adjustment | (3,107) | (3,107) | |||||||
Currency impact of long term funding | 302 | 302 | |||||||
Tax on currency impact of long term funding | 397 | 397 | |||||||
Unrealized capital gain - investments | 502 | 502 | |||||||
Amortization of interest rate hedge | (458) | (458) | |||||||
Total comprehensive income | 121,674 | (2,364) | 124,038 | ||||||
Exercise of share options (in shares) | 93,168 | ||||||||
Exercise of share options | 2,152 | $ 6 | 2,146 | ||||||
Issue of restricted/performance share units (in shares) | 407,547 | ||||||||
Issue of restricted/performance share units | 28 | 28 | |||||||
Share issuance costs | (9) | (9) | |||||||
Non-cash stock compensation expense | 20,690 | 20,690 | |||||||
Tax benefit on exercise of options | $ 2,338 | 2,338 | |||||||
Balance (in shares) at Jun. 30, 2016 | 55,459,627 | 55,459,627 | |||||||
Balance at Jun. 30, 2016 | $ 909,969 | $ 4,685 | $ 408,588 | $ 715 | $ (64,000) | $ 559,981 | |||
|
Basis of Presentation |
6 Months Ended |
---|---|
Jun. 30, 2016 | |
Basis of Presentation |
1. Basis of Presentation
These condensed consolidated financial statements, which have been
prepared in accordance with United States generally accepted
accounting principles (“US GAAP”), have not been
audited. The condensed consolidated financial statements reflect
all adjustments, which are, in the opinion of management, necessary
to present a fair statement of the operating results and financial
position for the periods presented. The preparation of the
condensed consolidated financial statements in conformity with US
GAAP requires management to make estimates and assumptions that
affect reported amounts and disclosures in the condensed
consolidated financial statements. Actual results could differ from
those estimates.
The condensed consolidated financial statements should be read in
conjunction with the accounting policies and notes to the
consolidated financial statements included in ICON’s Form
20-F for the year ended December 31, 2015. Operating results for
the three and six months ended June 30, 2016 are not necessarily
indicative of the results that may be expected for the fiscal
period ending December 31, 2016.
|
Goodwill |
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2016 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Goodwill |
2. Goodwill
|
Business Combinations |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Business Combinations |
3. Business Combinations
Acquisitions - PMG
On December 4, 2015 the Company acquired PMG, resulting in an
initial net cash outflow of $63.5 million, including certain
payments made on behalf of PMG totaling $9.9 million. PMG is
an integrated network of 48 clinical research sites in North
Carolina, South Carolina, Tennessee and Illinois. The site
network includes wholly owned facilities and dedicated clinical
research sites. PMG conducts clinical trials in all major
therapeutic areas and has particular expertise in vaccine,
gastroenterology, cardiovascular, neurology and endocrinology
studies. It has a proprietary database of clinical trial
participants. It also has access to in excess of 2
million active patients via electronic medical records through its
partnerships with healthcare institutions and community physical
practices. The acquisition agreement provides for
working capital targets to be achieved by PMG within 90 days of
acquisition. In March 2016, the Company agreed to pay an
additional $1.6 million on completion of this working capital
review. This amount was paid in April 2016.
The acquisition of PMG has been accounted for as a business
combination in accordance with FASB ASC 805 Business
Combinations. The Company has made a provisional
assessment of the fair value of assets acquired and liabilities
assumed as at that date. The table following summarizes the
Company’s provisional estimates of the fair values of the
assets acquired and liabilities assumed;
*Goodwill represents the acquisition of an established workforce
with experience in clinical trial consulting and regulatory support
for the development of drugs, medical devices and diagnostics, with
a specific focus on strategy to increase efficiency and
productivity in product development.
**The Company has made an initial estimate of separate intangible
assets acquired, being customer lists and order backlog, of $10.6
million. This assessment is under review and will be
finalized within 12 months of the date of acquisition.
Acquisitions - MediMedia Pharma Solutions
On February 27, 2015 the Company acquired MediMedia Pharma
Solutions for cash consideration of $104.7 million (net of working
capital adjustments of $4 million). In addition to the cash
consideration, certain payments were made on behalf of MediMedia
Pharma Solutions on completion totaling $11.3 million.
Headquartered in Yardley, Pennsylvania, MediMedia Pharma Solutions
includes MediMedia Managed Markets and Complete Healthcare
Communications. MediMedia Managed Markets is a leading provider of
strategic payer-validated market access solutions. Complete
Healthcare Communications is one of the leading medical and
scientific communication agencies working with medical affairs,
commercial and brand development teams within life science
companies. The acquisition agreement also provided for certain
working capital targets to be achieved by MediMedia Pharma
Solutions.
The acquisition of MediMedia Pharma Solutions has been accounted
for as a business combination in accordance with FASB ASC
805 Business
Combinations. The following table summarizes the
Company’s estimate of the fair values of the assets acquired
and liabilities assumed:
Acquisitions - Aptiv Solutions
On May 7, 2014 the Company acquired 100% of the common stock of
Aptiv Solutions (“Aptiv”), a global biopharmaceutical
and medical device development services company and leader in
adaptive clinical trials for cash consideration of $143.5 million,
including certain payments to be made on behalf of the company on
completion totaling $22.4 million. The acquisition agreement
provided for working capital targets to be achieved. On March
25, 2015, the Company received $2.0 million in respect of these
targets on completion of the working capital review. Aptiv
offers full-service clinical trial consulting and regulatory
support for drugs, medical devices and diagnostics with a specific
focus on strategies to increase product development efficiency and
productivity. It is a market leader in the integrated design and
execution of adaptive clinical trials for exploratory and late
phase development as well as being an industry leader in medical
device and diagnostic development in key medical technology
segments.
The acquisition of Aptiv has been accounted for as a business
combination in accordance with FASB ASC 805 Business
Combinations. The following table summarizes the fair values
of the assets acquired and the liabilities assumed:
*Goodwill represents the acquisition of an established workforce
with experience in clinical trial consulting and regulatory support
for the development of drugs, medical devices and diagnostics, with
a specific focus on strategy to increase efficiency and
productivity in product development. Goodwill related to the
US portion of the business acquired is tax deductible.
**Adjustments to cash consideration represent certain one-time
liabilities (including loan notes) identified at the acquisition
date which have subsequently been paid.
|
Restructuring |
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2016 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Restructuring |
4. Restructuring
Restructuring Charges
A restructuring charge of $4.1 million was recognized during the
three months ended June 30, 2016 under a restructuring plan adopted
following a review by the company of its operations. The
restructuring plan includes resource rationalizations in certain
areas of the business to improve resource utilization.
Details of the restructuring charge recognized in the three and six
months ended 30 June 2016 are as follows;
Details of the movement in the restructuring charge recognized in
the three and six months ended 30 June 2016 are as follows;
|
Income Taxes |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Income Taxes | 5. Income Taxes
Income taxes recognized during the three and six months ended June
30, 2016 comprise:
As at June 30, 2016 the Company maintains a $31.1 million liability
(December 31, 2015: $31.4 million) for unrecognized tax benefit,
which is comprised of $27.6 million (December 31, 2015: $28.1
million) related to items generating unrecognized tax benefits and
$3.5 million (December 31, 2015: $3.3 million) for interest and
related penalties to such items. The Company recognizes interest
accrued on unrecognized tax benefits as an additional income tax
expense.
The Company has analyzed filing positions in all of the significant
federal, state and foreign jurisdictions where it is required to
file income tax returns, as well as open tax years in these
jurisdictions. The only periods subject to examination by the major
tax jurisdictions where the Company does business are 2011 through
2015 tax years. The Company does not believe that the outcome of
any examination will have a material impact on its financial
statements.
|
Net income per ordinary share |
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2016 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Net income per ordinary share |
6. Net income per ordinary share
Basic net income per ordinary share has been computed by dividing
net income available to ordinary shareholders by the weighted
average number of ordinary shares outstanding during the period.
Diluted net income per ordinary share is computed by adjusting the
weighted average number of ordinary shares outstanding during the
period for all potentially dilutive ordinary shares outstanding
during the period and adjusting net income for any changes in
income or loss that would result from the conversion of such
potential ordinary shares. There is no difference in net income
used for basic and diluted net income per ordinary share.
The reconciliation of the number of shares used in the computation
of basic and diluted net income per ordinary share is as
follows:
|
Share-based Awards |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-based Awards |
7. Share-based Awards
Share Options
On July 21, 2008 the Company adopted the Employee Share Option Plan
2008 (the “2008 Employee Plan”) pursuant to which the
Compensation and Organization Committee of the Company’s
Board of Directors may grant options to any employee, or any
Director holding a salaried office or employment with the Company
or a Subsidiary for the purchase of ordinary shares. On the same
date, the Company also adopted the Consultants Share Option Plan
2008 (the “2008 Consultants Plan”), pursuant to which
the Compensation and Organization Committee of the Company’s
Board of Directors may grant options to any consultant, adviser or
non-executive Director retained by the Company or any Subsidiary
for the purchase of ordinary shares.
Each option granted under the 2008 Employee Plan or the 2008
Consultants Plan (together the “2008 Option Plans”)
will be an employee stock option, or Non-qualifying Stock Options
(‘NSO’), as described in Section 422 or 423 of the
Internal Revenue Code. Each grant of an option under the 2008
Options Plans will be evidenced by a Stock Option Agreement between
the optionee and the Company. The exercise price will be specified
in each Stock Option Agreement, however option prices will not be
less than 100% of the fair market value of an ordinary share on the
date the option is granted.
An aggregate of 6.0 million ordinary shares have been reserved
under the 2008 Employee Plan, as reduced by any shares issued or to
be issued pursuant to options granted under the 2008 Consultants
Plan, under which a limit of 400,000 shares applies. Further,
the maximum number of ordinary shares with respect to which options
may be granted under the 2008 Employee Option Plan, during any
calendar year to any employee shall be 400,000 ordinary
shares. There is no individual limit under the 2008
Consultants Plan. No options may be granted under the
2008 Option Plans after July 21, 2018.
On January 17, 2003 the Company adopted the Share Option Plan 2003
(the “2003 Share Option Plan”) pursuant to which the
Compensation and Organization Committee of the Board could grant
options to officers and other employees of the Company or its
subsidiaries for the purchase of ordinary shares. An
aggregate of 6.0 million ordinary shares were reserved under the
2003 Share Option Plan; and, in no event could the number of
ordinary shares issued pursuant to options awarded under this plan
exceed 10% of the outstanding shares, as defined in the 2003 Share
Option Plan, at the time of the grant, unless the Board expressly
determined otherwise. Further, the maximum number of ordinary
shares with respect to which options could be granted under the
2003 Share Option Plan during any calendar year to any employee was
400,000 ordinary shares. The 2003 Share Option Plan expired
on January 17, 2013. No new options may be granted under this
plan.
Share option awards are granted with an exercise price equal to the
market price of the Company’s shares at date of grant.
Share options typically vest over a period of five years from date
of grant and expire eight years from date of grant. The
maximum contractual term of options outstanding at June 30, 2016 is
eight years.
The following table summarizes option activity for the six months
ended June 30, 2016:
The Company has outstanding options with fair values ranging from
$5.88 to $20.78 per option or a weighted average fair value of
$10.62 per option. The Company issues ordinary shares for all
options exercised. The total amount of fully vested share options
which remained outstanding at June 30, 2016, was 886,188. Fully
vested share options at June 30, 2016, have an average remaining
contractual term of 3.50 years, an average exercise price of $28.36
and a total intrinsic value of $36.9 million. The total intrinsic
value of options exercised during the six months ended June 30,
2016 was $4.1 million (June 30, 2015: $12.6 million).
The following table summarizes the movement in non-vested share
options for the six months ended June 30, 2016:
Fair value of Stock Options Assumptions
The weighted average fair value of options granted during the six
months ended June 30, 2016 and June 30, 2015 was calculated using
the Black-Scholes option pricing model. The weighted average
fair values and assumptions used were as follows:
Expected volatility is based on the historical volatility of our
common stock over a period equal to the expected term of the
options; the expected life represents the weighted average period
of time that options granted are expected to be outstanding given
consideration to vesting schedules and our historical experience of
past vesting and termination patterns. The risk-free rate is based
on the U.S. government zero-coupon bonds yield curve in effect at
time of the grant for periods corresponding with the expected life
of the option.
Restricted Share Units and Performance Share Units
On July 21, 2008 the Company adopted the 2008 Employees Restricted
Share Unit Plan (the “2008 RSU Plan”) pursuant to which
the Compensation and Organization Committee of the Company’s
Board of Directors may select any employee, or any Director holding
a salaried office or employment with the Company, or a Subsidiary
to receive an award under the plan. An aggregate of 1.0
million ordinary shares have been reserved for issuance under the
2008 RSU Plan.
On April 23, 2013 the Company adopted the 2013 Employees Restricted
Share Unit and Performance Share Unit Plan (the “2013 RSU
Plan”) pursuant to which the Compensation and Organization
Committee of the Company’s Board of Directors may select any
employee, or any Director holding a salaried office or employment
with the Company, or a Subsidiary to receive an award under the
plan. On May 11, 2015 the 2013 RSU Plan was amended and
restated in order to increase the number of shares that can be
issued under the RSU Plan by 2.5 million shares. Accordingly,
an aggregate of 4.1 million ordinary shares have been reserved for
issuance under the 2013 RSU Plan. The shares are awarded at
par value and vest over a service period. Awards under the 2013 RSU
Plan may be settled in cash or shares at the option of the
Company.
The Company has awarded RSUs and PSUs to certain key individuals of
the Group. The following table summarizes RSU and PSU activity for
the six months ended June 30, 2016:
The fair value of RSUs vested for the six months ended June 30,
2016 totaled $5.4 million (full year 2015: $7.0 million).
The fair value of PSUs vested for the six months ended June 30,
2016 totaled $8.2 million (the fair value of PSUs vested for the
full year 2015 was $0.3 million).
The PSUs vest based on service and specified EPS targets over the
period 2013 – 2016, 2014 – 2017, 2015 – 2018 and
2016 - 2019. Since 2013, 482,626 PSUs (net of forfeitures) have
been granted. Depending on the actual amount of EPS from 2013
to 2019, up to an additional 413,101 PSUs may also be
granted.
Non-cash stock compensation expense
Non-cash stock compensation expense for the three and six months
ended June 30, 2016 has been allocated as follows:
Total non-cash stock compensation expense not yet recognized at
June 30, 2016 amounted to $87.9 million. The weighted average
period over which this is expected to be recognized is 2.4
years . Total tax benefit
recognized in additional paid in capital related to the non-cash
compensation expense amounted to $2.3 million for the six months
ended June 30, 2016 (June 30, 2015: $2.5 million).
|
Business Segment Information |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Business Segment Information |
8. Business Segment Information
The Company determines and presents operating segments based on the
information that is internally provided to the Chief Executive
Officer, Chief Financial Officer and Chief Operating Officer, who
together are considered the Company’s chief operating
decision maker, in accordance with FASB ASC 280-10 Disclosures
about Segments of an Enterprises and Related
Information.
The Company is a contract research organization
(“CRO”), providing outsourced development services on a
global basis to the pharmaceutical, biotechnology and medical
device industries. It specializes in the strategic development,
management and analysis of programs that support all stages of the
clinical development process - from compound selection to Phase
I-IV clinical studies. The Company has the expertise and
capability to conduct clinical trials in most major therapeutic
areas on a global basis and has the operational flexibility to
provide development services on a stand-alone basis or as part of
an integrated “full service” solution. The
Company has expanded predominately through internal growth,
together with a number of strategic acquisitions to enhance its
expertise and capabilities in certain areas of the clinical
development process.
The Company is generally awarded projects based upon responses to
requests for proposals received from companies in the
pharmaceutical, biotechnology and medical device industries or work
orders executed under our strategic partnership arrangements.
Contracts with customers are generally entered into centrally, in
most cases with ICON Clinical Research Limited (“ICON
Ireland”), the Company’s principal operating subsidiary
in Ireland. Revenues, which consist primarily of fees earned
under these contracts, are allocated to individual entities within
the Group, based on where the work is performed in accordance with
the Company’s global transfer pricing model.
ICON Ireland acts as the group entrepreneur under the
Company’s global transfer pricing model given its role in the
development and management of the group, it’s ownership of
key intellectual property and customer relationships, its key role
in the mitigation of risks faced by the group and its
responsibility for maintaining the Company’s global
network. As such it enters into the majority of the
Company’s customer contracts.
ICON Ireland remunerates other operating entities in the ICON Group
on the basis of a guaranteed cost plus mark up for the services
they perform in each of their local territories. The cost
plus mark up for each ICON entity is established to ensure that
each of ICON Ireland and the ICON entities that are involved in the
conduct of services for customers, earn an appropriate arms-length
return having regard to the assets owned, risks borne, and
functions performed by each entity from these intercompany
transactions. The cost plus mark-up policy is reviewed annually to
ensure that it is market appropriate.
The geographic split of revenue disclosed for each region outside
Ireland is the cost plus revenue attributable to these entities.
The residual revenues of the Group, once each ICON entity has been
paid its respective intercompany service fee, generally fall to be
retained by ICON Ireland. As such revenues and income from
operations in Ireland are a function of this global transfer
pricing model and comprise net revenues of the Group after
deducting the cost plus revenues attributable to the activities
performed outside Ireland.
The Company's areas of operation outside of Ireland include the
United States, United Kingdom, France, Germany, Italy, Spain, The
Netherlands, Sweden, Turkey, Poland, Czech Republic, Latvia,
Russia, Ukraine, Hungary, Israel, Romania, Switzerland, Canada,
Mexico, Brazil, Colombia, Argentina, Chile, Peru, India, China,
South Korea, Japan, Thailand, Taiwan, Singapore, The Philippines,
Australia, New Zealand, and South Africa.
Segment information as at June 30, 2016 and December 31, 2015 and
for the three and six months ended June 30, 2016 and June 30, 2015
is as follows:
a) The distribution of net revenue by geographical area was as
follows:
* All
sales shown for Ireland are export sales.
b) The distribution of income from operations, including
restructuring, by geographical area was as follows:
c) The distribution of income from operations, excluding
restructuring, by geographical area was as follows:
d) The distribution of property, plant and equipment, net, by
geographical area was as follows:
e) The distribution of depreciation and amortization by
geographical area was as follows:
f) The distribution of total assets by geographical area was as
follows:
* The
December 31, 2015 Balance Sheet has been retrospectively restated
as required to reflect the requirements of new guidance in respect
of the presentation of debt issue costs.
|
Goodwill (Tables) |
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2016 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Goodwill |
|
Business Combinations (Tables) |
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2016 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PMG | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of Estimates of Fair Values of Assets Acquired and Liabilities Assumed | The
table following summarizes the Company’s provisional
estimates of the fair values of the assets acquired and liabilities
assumed;
*Goodwill represents the acquisition of an established workforce
with experience in clinical trial consulting and regulatory support
for the development of drugs, medical devices and diagnostics, with
a specific focus on strategy to increase efficiency and
productivity in product development.
**The Company has made an initial estimate of separate intangible
assets acquired, being customer lists and order backlog, of $10.6
million. This assessment is under review and will be
finalized within 12 months of the date of acquisition.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
MediMedia Pharma Solutions | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of Estimates of Fair Values of Assets Acquired and Liabilities Assumed | The
following table summarizes the Company’s estimate of the fair
values of the assets acquired and liabilities assumed:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Aptiv Solutions | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of Estimates of Fair Values of Assets Acquired and Liabilities Assumed |
The following table summarizes the fair values of the assets
acquired and the liabilities assumed:
*Goodwill represents the acquisition of an established workforce
with experience in clinical trial consulting and regulatory support
for the development of drugs, medical devices and diagnostics, with
a specific focus on strategy to increase efficiency and
productivity in product development. Goodwill related to the US
portion of the business acquired is tax deductible.
**Adjustments to cash consideration represent certain one-time
liabilities (including loan notes) identified at the acquisition
date which have subsequently been paid.
|
Restructuring (Tables) |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Details of restructuring charge recognized |
Details of the restructuring charge recognized in the three and six
months ended 30 June 2016 are as follows;
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Details of Movement in Restructuring Provisions Recognized |
Details of the movement in the restructuring charge recognized in
the three and six months ended 30 June 2016 are as follows;
|
Income Taxes (Tables) |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Income Taxes Recognized During Period |
Income taxes recognized during the three and six months ended June
30, 2016 comprise:
|
Net income per ordinary share (Tables) |
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2016 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reconciliation of Number of Shares Used in Computation of Basic and Diluted Net Income Per Ordinary Share |
The reconciliation of the number of shares used in the computation
of basic and diluted net income per ordinary share is as
follows:
|
Share-based Awards (Tables) |
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2016 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of Stock Option Activity |
The following table summarizes option activity for the six months
ended June 30, 2016:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of Movement in Non-Vested Share Options | The following table summarizes the movement in non-vested
share options for the six months ended June 30, 2016:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Weighted Average Fair Values and Assumptions Used |
The weighted average fair values and assumptions used were as
follows:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
RSU and PSU Activity | The
following table summarizes RSU and PSU activity for the six months
ended June 30, 2016:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Non-cash Stock Compensation Expense |
Non-cash stock compensation expense for the three and six months
ended June 30, 2016 has been allocated as follows:
|
Business Segment Information (Tables) |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Distribution of Net Revenue by Geographical Area | a) The distribution of net revenue by geographical area was as
follows:
*
All sales shown for Ireland are export sales.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Distribution of Income from Operations by Geographical Area | b) The distribution of income from operations, including
restructuring, by geographical area was as follows:
c) The distribution of income from operations, excluding
restructuring, by geographical area was as follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Distribution of Property, Plant and Equipment, Net, by Geographical Area |
d) The distribution of property, plant and equipment, net, by
geographical area was as follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Distribution of Depreciation and Amortization by Geographical Area |
e) The distribution of depreciation and amortization by
geographical area was as follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Distribution of Total Assets by Geographical Area |
f) The distribution of total assets by geographical area was as
follows:
*
The December 31, 2015 Balance Sheet has been retrospectively
restated as required to reflect the requirements of new guidance in
respect of the presentation of debt issue costs.
|
Goodwill (Detail) - USD ($) $ in Thousands |
6 Months Ended | 12 Months Ended | ||||
---|---|---|---|---|---|---|
Jun. 30, 2016 |
Dec. 31, 2015 |
|||||
Goodwill [Line Items] | ||||||
Opening balance | $ 588,434 | [1] | $ 463,324 | |||
Current period acquisitions (Note 3) | 133,123 | |||||
Prior period acquisitions (Note 3) | 5,773 | 4,418 | ||||
Foreign exchange movement | (3,779) | (12,431) | ||||
Closing balance | $ 590,428 | $ 588,434 | [1] | |||
|
Business Combinations - Additional Information (Detail) $ in Thousands |
1 Months Ended | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2016
USD ($)
|
Dec. 04, 2015
USD ($)
Patient
Site
|
Mar. 25, 2015
USD ($)
|
Feb. 27, 2015
USD ($)
|
May 07, 2014
USD ($)
|
Apr. 30, 2016
USD ($)
|
||||||
PMG | |||||||||||
Business Acquisition [Line Items] | |||||||||||
Net cash outflow | $ 63,500 | ||||||||||
Other liabilities assumed | $ 9,860 | ||||||||||
Number of clinical research sites acquired | Site | 48 | ||||||||||
Working capital targets achievement period | 90 days | ||||||||||
Working capital adjustment | $ 1,600 | $ 1,613 | |||||||||
Working capital adjustment, cash paid | $ 1,613 | ||||||||||
Cash consideration | $ 53,681 | ||||||||||
PMG | Minimum | |||||||||||
Business Acquisition [Line Items] | |||||||||||
Number of active patients via electronic medical records acquired | Patient | 2,000,000 | ||||||||||
MediMedia Pharma Solutions | |||||||||||
Business Acquisition [Line Items] | |||||||||||
Net cash outflow | $ 116,002 | ||||||||||
Other liabilities assumed | [1] | 11,283 | |||||||||
Working capital adjustment | 3,998 | ||||||||||
Cash consideration, net of working capital adjustment | 104,700 | ||||||||||
Cash consideration | $ 108,717 | ||||||||||
Aptiv Solutions | |||||||||||
Business Acquisition [Line Items] | |||||||||||
Working capital adjustment | $ 2,000 | $ 1,964 | |||||||||
Percentage of common stock acquired | 100.00% | ||||||||||
Cash consideration | $ 143,500 | ||||||||||
Adjustments to cash consideration | [2] | $ 22,399 | |||||||||
|
Summary of Estimates of Fair Values of Assets Acquired and Liabilities Assumed of PMG (Detail) - USD ($) $ in Thousands |
6 Months Ended | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2016 |
Dec. 04, 2015 |
Jun. 30, 2016 |
Jun. 30, 2015 |
Dec. 31, 2015 |
[1] | Dec. 31, 2014 |
||||||||
Business Acquisition [Line Items] | ||||||||||||||
Goodwill | $ 590,428 | $ 588,434 | $ 463,324 | |||||||||||
Total cash outflows | $ 1,613 | $ 103,139 | ||||||||||||
PMG | ||||||||||||||
Business Acquisition [Line Items] | ||||||||||||||
Cash | $ 194 | |||||||||||||
Property, plant and equipment | 712 | |||||||||||||
Goodwill | [2] | 46,812 | ||||||||||||
Intangible assets | [3] | 10,582 | ||||||||||||
Accounts receivable | 12,747 | |||||||||||||
Prepayments and other current assets | 1,329 | |||||||||||||
Accounts payable | (530) | |||||||||||||
Other liabilities | (2,459) | |||||||||||||
Non-current deferred tax liability | (4,233) | |||||||||||||
Net assets acquired | 65,154 | |||||||||||||
Cash consideration | 53,681 | |||||||||||||
Other liabilities assumed | 9,860 | |||||||||||||
Working capital adjustment | $ 1,600 | 1,613 | ||||||||||||
Total cash outflows | $ 65,154 | |||||||||||||
|
Summary of Estimates of Fair Values of Assets Acquired and Liabilities Assumed of PMG (Parenthetical) (Detail) - PMG $ in Thousands |
Dec. 04, 2015
USD ($)
|
|||
---|---|---|---|---|
Business Acquisition [Line Items] | ||||
Intangible asset | $ 10,582 | [1] | ||
Customer Lists | ||||
Business Acquisition [Line Items] | ||||
Intangible asset | $ 10,600 | |||
|
Summary of Estimates of Fair Values of Assets Acquired and Liabilities Assumed of MediMedia Pharma Solutions (Detail) - USD ($) $ in Thousands |
Feb. 27, 2015 |
Jun. 30, 2016 |
Dec. 31, 2015 |
[1] | Dec. 31, 2014 |
|||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Business Acquisition [Line Items] | ||||||||||||
Goodwill | $ 590,428 | $ 588,434 | $ 463,324 | |||||||||
MediMedia Pharma Solutions | ||||||||||||
Business Acquisition [Line Items] | ||||||||||||
Property, plant and equipment | $ 1,049 | |||||||||||
Goodwill | [2] | 92,084 | ||||||||||
Accounts receivable | 5,240 | |||||||||||
Unbilled revenue | 4,324 | |||||||||||
Prepayments and other current assets | 621 | |||||||||||
Accounts payable | (749) | |||||||||||
Payments on account | (4,186) | |||||||||||
Deferred tax liability | (2,171) | |||||||||||
Other liabilities | (5,483) | |||||||||||
Net assets acquired | 116,002 | |||||||||||
Cash consideration | 108,717 | |||||||||||
Other liabilities assumed | [3] | 11,283 | ||||||||||
Gross cash outflows | 120,000 | |||||||||||
Working capital adjustment | (3,998) | |||||||||||
Net cash outflows | 116,002 | |||||||||||
MediMedia Pharma Solutions | Customer Lists | ||||||||||||
Business Acquisition [Line Items] | ||||||||||||
Intangible asset | 22,752 | |||||||||||
MediMedia Pharma Solutions | Order Backlog | ||||||||||||
Business Acquisition [Line Items] | ||||||||||||
Intangible asset | $ 2,521 | |||||||||||
|
Summary of Estimates of Fair Values of Assets Acquired and Liabilities Assumed of MediMedia Pharma Solutions (Parenthetical) (Detail) $ in Thousands |
Feb. 27, 2015
USD ($)
|
|||
---|---|---|---|---|
MediMedia Pharma Solutions | ||||
Business Acquisition [Line Items] | ||||
Other liabilities assumed | $ 11,283 | [1] | ||
|
Summary of Estimates of Fair Values of Assets Acquired and Liabilities Assumed of Aptiv Solutions (Detail) - USD ($) $ in Thousands |
Mar. 25, 2015 |
May 07, 2014 |
Jun. 30, 2016 |
Dec. 31, 2015 |
[1] | Dec. 31, 2014 |
|||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Business Acquisition [Line Items] | |||||||||||||
Goodwill | $ 590,428 | $ 588,434 | $ 463,324 | ||||||||||
Aptiv Solutions | |||||||||||||
Business Acquisition [Line Items] | |||||||||||||
Property, plant and equipment | $ 6,924 | ||||||||||||
Goodwill | [2] | 125,627 | |||||||||||
Cash and cash equivalents | 3,484 | ||||||||||||
Accounts receivable | 25,091 | ||||||||||||
Unbilled revenue | 21,154 | ||||||||||||
Prepayments and other current assets | 4,180 | ||||||||||||
Non-current assets | 2,911 | ||||||||||||
Accounts payable | (9,565) | ||||||||||||
Other liabilities | (29,782) | ||||||||||||
Payments on account | (31,094) | ||||||||||||
Non-current other liabilities | (11,303) | ||||||||||||
Loan notes payable | [3] | (17,790) | |||||||||||
Net assets acquired | 119,137 | ||||||||||||
Cash consideration | 143,500 | ||||||||||||
Working capital adjustment | $ (2,000) | (1,964) | |||||||||||
Gross cash outflows | 141,536 | ||||||||||||
Adjustments to cash consideration | [3] | (22,399) | |||||||||||
Net assets acquired/Net purchase consideration | 119,137 | ||||||||||||
Aptiv Solutions | Customer Relationships | |||||||||||||
Business Acquisition [Line Items] | |||||||||||||
Intangible asset | 21,400 | ||||||||||||
Aptiv Solutions | Order Backlog | |||||||||||||
Business Acquisition [Line Items] | |||||||||||||
Intangible asset | $ 7,900 | ||||||||||||
|
Restructuring - Additional Information (Detail) - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended |
---|---|---|
Jun. 30, 2016 |
Jun. 30, 2016 |
|
Restructuring Cost and Reserve [Line Items] | ||
Restructuring charges | $ 4,094 | $ 4,094 |
Details of restructuring charge recognized (Detail) - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended |
---|---|---|
Jun. 30, 2016 |
Jun. 30, 2016 |
|
Restructuring Cost and Reserve [Line Items] | ||
Restructuring charges | $ 4,094 | $ 4,094 |
Total | $ 4,094 | $ 4,094 |
Details of Movement in Restructuring Provisions Recognized (Detail) - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended |
---|---|---|
Jun. 30, 2016 |
Jun. 30, 2016 |
|
Restructuring Cost and Reserve [Line Items] | ||
Initial restructuring charge recorded | $ (4,094) | $ (4,094) |
Workforce reduction | ||
Restructuring Cost and Reserve [Line Items] | ||
Initial restructuring charge recorded | 4,094 | 4,094 |
Cash payments | (901) | (901) |
Foreign exchange movement | 0 | 0 |
Closing provision | $ 3,193 | $ 3,193 |
Income Taxes Recognized During Period (Detail) - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Jun. 30, 2016 |
Jun. 30, 2015 |
Jun. 30, 2016 |
Jun. 30, 2015 |
|
Reconciliation of Provision of Income Taxes [Line Items] | ||||
Provision for income taxes before restructuring and other items | $ 10,526 | $ 9,537 | $ 20,691 | $ 20,338 |
Tax impact of restructuring and other items | (512) | (512) | ||
Provision for income taxes after restructuring and other items | $ 10,014 | $ 9,537 | $ 20,179 | $ 20,338 |
Income Taxes - Additional Information (Detail) - USD ($) $ in Millions |
6 Months Ended | |
---|---|---|
Jun. 30, 2016 |
Dec. 31, 2015 |
|
Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items] | ||
Liability for unrecognized tax benefit | $ 31.1 | $ 31.4 |
Items generating unrecognized tax benefits | 27.6 | 28.1 |
Interest and related penalties | $ 3.5 | $ 3.3 |
Earliest Tax Year | ||
Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items] | ||
Tax year subject to examination by major tax jurisdictions | 2011 | |
Latest Tax Year | ||
Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items] | ||
Tax year subject to examination by major tax jurisdictions | 2015 |
Reconciliation of Number of Shares Used in Computation of Basic and Diluted Net Income Per Ordinary Share (Detail) - shares |
3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Jun. 30, 2016 |
Jun. 30, 2015 |
Jun. 30, 2016 |
Jun. 30, 2015 |
|
Schedule of Weighted Average Number of Diluted Shares Outstanding [Line Items] | ||||
Weighted average number of ordinary shares outstanding for basic net income per ordinary share | 55,318,923 | 60,244,982 | 55,164,971 | 60,263,021 |
Effect of dilutive share options outstanding | 1,261,876 | 1,556,705 | 1,262,545 | 1,586,305 |
Weighted average number of ordinary shares outstanding for diluted net income per ordinary share | 56,580,799 | 61,801,687 | 56,427,516 | 61,849,326 |
Share-based Awards - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands |
6 Months Ended | 12 Months Ended | 39 Months Ended | ||
---|---|---|---|---|---|
May 11, 2015 |
Jun. 30, 2016 |
Jun. 30, 2015 |
Dec. 31, 2015 |
Mar. 31, 2016 |
|
Compensation Related Costs Share Based Payments Disclosure [Line Items] | |||||
Non-cash stock compensation expense not yet recognized | $ 87,900 | ||||
Unrecognized stock-based compensation expense, weighted average period (years) | 2 years 4 months 24 days | ||||
Tax benefit on exercise of options | $ 2,338 | $ 2,500 | |||
Restricted Stock Units (RSUs) | |||||
Compensation Related Costs Share Based Payments Disclosure [Line Items] | |||||
Fair value of stock units vested | $ 5,400 | $ 7,000 | |||
Stock units granted | 368,889 | ||||
Performance Share Unit (PSUs) | |||||
Compensation Related Costs Share Based Payments Disclosure [Line Items] | |||||
Fair value of stock units vested | $ 8,200 | $ 300 | |||
Stock units granted | 247,992 | ||||
PSUs Based on Service and EPS Targets | |||||
Compensation Related Costs Share Based Payments Disclosure [Line Items] | |||||
Stock units granted | 482,626 | ||||
PSUs Based on Service and EPS Targets | Minimum | |||||
Compensation Related Costs Share Based Payments Disclosure [Line Items] | |||||
Cumulative EPS vesting period | 2013 | ||||
PSUs Based on Service and EPS Targets | Maximum | |||||
Compensation Related Costs Share Based Payments Disclosure [Line Items] | |||||
Stock units to be granted | 413,101 | ||||
Cumulative EPS vesting period | 2019 | ||||
Employee Stock Plan, 2008 Plan | |||||
Compensation Related Costs Share Based Payments Disclosure [Line Items] | |||||
Ordinary shares which have been reserved for issuance | 6,000,000 | ||||
Employee Stock Plan, 2008 Plan | Individual Employee | |||||
Compensation Related Costs Share Based Payments Disclosure [Line Items] | |||||
Ordinary shares which have been reserved for issuance | 400,000 | ||||
Employee Stock Plan, 2008 Plan | Minimum | |||||
Compensation Related Costs Share Based Payments Disclosure [Line Items] | |||||
Percentage of option price for fair value of ordinary share | 100.00% | ||||
Employee Stock Plan, 2003 Plan | |||||
Compensation Related Costs Share Based Payments Disclosure [Line Items] | |||||
Ordinary shares which have been reserved for issuance | 6,000,000 | ||||
Maximum number of award as percentage of shares outstanding | 10.00% | ||||
Employee Stock Plan, 2003 Plan | Individual Employee | |||||
Compensation Related Costs Share Based Payments Disclosure [Line Items] | |||||
Ordinary shares which have been reserved for issuance | 400,000 | ||||
Employee Stock Option | |||||
Compensation Related Costs Share Based Payments Disclosure [Line Items] | |||||
Shares vesting period | 5 years | ||||
Shares expiration period | 8 years | ||||
Weighted average contractual term of options outstanding | 4 years 9 months 29 days | ||||
Weighted average fair value per option | $ 10.62 | ||||
Exercisable - number of shares | 886,188 | ||||
Exercisable - weighted average remaining contractual life | 3 years 6 months | ||||
Exercisable - weighted average exercise price | $ 28.36 | ||||
Fully vested total intrinsic value | $ 36,900 | ||||
Intrinsic value of option exercised | $ 4,100 | $ 12,600 | |||
Employee Stock Option | Minimum | |||||
Compensation Related Costs Share Based Payments Disclosure [Line Items] | |||||
Options outstanding fair value | $ 5.88 | ||||
Employee Stock Option | Maximum | |||||
Compensation Related Costs Share Based Payments Disclosure [Line Items] | |||||
Weighted average contractual term of options outstanding | 8 years | ||||
Options outstanding fair value | $ 20.78 | ||||
Restricted Stock Units 2008 | |||||
Compensation Related Costs Share Based Payments Disclosure [Line Items] | |||||
Ordinary shares which have been reserved for issuance | 1,000,000 | ||||
Restricted Stock Units 2013 | |||||
Compensation Related Costs Share Based Payments Disclosure [Line Items] | |||||
Ordinary shares which have been reserved for issuance | 4,100,000 | ||||
Number of additional shares authorized for issuance | 2,500,000 |
Summary of Stock Option Activity (Detail) - Employee Stock Option - $ / shares |
6 Months Ended | |
---|---|---|
Jun. 30, 2016 |
Jun. 30, 2015 |
|
Options Outstanding Number of Shares | ||
Outstanding at beginning of period | 1,626,582 | |
Granted | 256,191 | |
Exercised | (93,168) | |
Forfeited | (9,765) | |
Outstanding at end of period | 1,779,840 | |
Exercisable at end of period | 886,188 | |
Weighted Average Exercise Price | ||
Outstanding at beginning of period | $ 34.87 | |
Granted | 69.61 | |
Exercised | 23.10 | |
Forfeited | 22.48 | |
Outstanding at end of period | 40.55 | |
Exercisable at end of period | 28.36 | |
Weighted Average Fair Value | ||
Outstanding at beginning of period | 11.94 | |
Granted | 20.10 | $ 19.75 |
Exercised | 9.35 | |
Forfeited | 9.57 | |
Outstanding at end of period | 13.26 | |
Exercisable at end of period | $ 10.41 | |
Weighted Average Remaining Contractual Life | ||
Outstanding at end of period | 4 years 9 months 29 days | |
Exercisable at end of period | 3 years 6 months |
Summary of Movement in Non-Vested Share Options (Detail) - Employee Stock Option - $ / shares |
6 Months Ended | |
---|---|---|
Jun. 30, 2016 |
Jun. 30, 2015 |
|
Options Outstanding Number of Shares | ||
Beginning Balance | 968,853 | |
Granted | 256,191 | |
Vested | (324,315) | |
Forfeited | (7,077) | |
Ending Balance | 893,652 | |
Weighted Average Exercise Price | ||
Beginning balance | $ 42.14 | |
Granted | 69.61 | |
Vested | 35.35 | |
Forfeited | 21.97 | |
Ending balance | 52.64 | |
Weighted Average Fair Value | ||
Beginning Balance | 13.69 | |
Granted | 20.10 | $ 19.75 |
Vested | 12.22 | |
Forfeited | 9.52 | |
Ending Balance | $ 16.10 |
Schedule of Weighted Average Fair Values and Assumptions Used (Detail) - Employee Stock Option - $ / shares |
6 Months Ended | |
---|---|---|
Jun. 30, 2016 |
Jun. 30, 2015 |
|
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Weighted average fair value | $ 20.10 | $ 19.75 |
Assumptions: | ||
Expected volatility | 30.00% | 30.00% |
Dividend yield | 0.00% | 0.00% |
Risk-free interest rate | 1.39% | 1.58% |
Expected life | 5 years | 5 years |
Summary of RSU and PSU Activity (Detail) - $ / shares |
6 Months Ended | 12 Months Ended |
---|---|---|
Jun. 30, 2016 |
Dec. 31, 2015 |
|
Performance Share Unit (PSUs) | ||
Outstanding Number of Shares | ||
Outstanding at beginning of period | 901,773 | |
Granted | 247,992 | |
Shares vested | (253,602) | |
Forfeited | (436) | |
Outstanding at ending of period | 895,727 | 901,773 |
Weighted Average Fair Value | ||
Outstanding at beginning of period | $ 48.33 | |
Granted | 71.58 | |
Shares vested | 32.38 | |
Forfeited | 31.49 | |
Outstanding at end of period | $ 57.78 | $ 48.33 |
Weighted Average Remaining Contractual Life | ||
Outstanding at end of period | 1 year 5 months 1 day | 1 year 2 months 19 days |
Restricted Stock Units (RSUs) | ||
Outstanding Number of Shares | ||
Outstanding at beginning of period | 1,067,613 | |
Granted | 368,889 | |
Shares vested | (153,945) | |
Forfeited | (57,331) | |
Outstanding at ending of period | 1,225,226 | 1,067,613 |
Weighted Average Fair Value | ||
Outstanding at beginning of period | $ 48.30 | |
Granted | 66.81 | |
Shares vested | 35.33 | |
Forfeited | 49.68 | |
Outstanding at end of period | $ 55.44 | $ 48.30 |
Weighted Average Remaining Contractual Life | ||
Outstanding at end of period | 1 year 7 months 24 days | 1 year 5 months 23 days |
Schedule of Non-cash Stock Compensation Expense (Detail) - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Jun. 30, 2016 |
Jun. 30, 2015 |
Jun. 30, 2016 |
Jun. 30, 2015 |
|
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Share-based compensation expense | $ 11,099 | $ 8,969 | $ 20,690 | $ 15,012 |
Direct costs | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Share-based compensation expense | 5,790 | 4,636 | 11,075 | 7,966 |
Selling, general and administrative | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Share-based compensation expense | $ 5,309 | $ 4,333 | $ 9,615 | $ 7,046 |
Distribution of Net Revenue by Geographical Area (Detail) - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Jun. 30, 2016 |
Jun. 30, 2015 |
Jun. 30, 2016 |
Jun. 30, 2015 |
|
Segment Reporting Information [Line Items] | ||||
Net Revenue | $ 410,630 | $ 388,657 | $ 811,152 | $ 776,888 |
Ireland | ||||
Segment Reporting Information [Line Items] | ||||
Net Revenue | 95,653 | 105,413 | 196,488 | 219,503 |
Rest Of Europe | ||||
Segment Reporting Information [Line Items] | ||||
Net Revenue | 79,436 | 78,540 | 155,078 | 162,628 |
United States | ||||
Segment Reporting Information [Line Items] | ||||
Net Revenue | 193,377 | 164,300 | 377,467 | 314,364 |
Rest of World | ||||
Segment Reporting Information [Line Items] | ||||
Net Revenue | $ 42,164 | $ 40,404 | $ 82,119 | $ 80,393 |
Distribution of Income from operations, including Restructuring, by Geographical Are (Detail) - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Jun. 30, 2016 |
Jun. 30, 2015 |
Jun. 30, 2016 |
Jun. 30, 2015 |
|
Segment Reporting Information [Line Items] | ||||
Income from operations | $ 73,927 | $ 68,131 | $ 149,937 | $ 134,805 |
Ireland | ||||
Segment Reporting Information [Line Items] | ||||
Income from operations | 54,597 | 49,436 | 114,148 | 97,002 |
Rest Of Europe | ||||
Segment Reporting Information [Line Items] | ||||
Income from operations | 4,863 | 3,521 | 8,307 | 10,307 |
United States | ||||
Segment Reporting Information [Line Items] | ||||
Income from operations | 11,826 | 12,592 | 22,610 | 22,447 |
Rest of World | ||||
Segment Reporting Information [Line Items] | ||||
Income from operations | $ 2,641 | $ 2,582 | $ 4,872 | $ 5,049 |
Distribution of Income from operations, excluding Restructuring, by Geographical Area (Detail) - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Jun. 30, 2016 |
Jun. 30, 2015 |
Jun. 30, 2016 |
Jun. 30, 2015 |
|
Segment Reporting Information [Line Items] | ||||
Income from operations, excluding restructuring and other items | $ 78,021 | $ 68,131 | $ 154,031 | $ 134,805 |
Ireland | ||||
Segment Reporting Information [Line Items] | ||||
Income from operations, excluding restructuring and other items | 58,326 | 49,436 | 117,877 | 97,002 |
Rest Of Europe | ||||
Segment Reporting Information [Line Items] | ||||
Income from operations, excluding restructuring and other items | 5,171 | 3,521 | 8,615 | 10,307 |
United States | ||||
Segment Reporting Information [Line Items] | ||||
Income from operations, excluding restructuring and other items | 11,826 | 12,592 | 22,610 | 22,447 |
Rest of World | ||||
Segment Reporting Information [Line Items] | ||||
Income from operations, excluding restructuring and other items | $ 2,698 | $ 2,582 | $ 4,929 | $ 5,049 |
Distribution of Property, Plant and Equipment, Net, by Geographical Area (Detail) - USD ($) $ in Thousands |
Jun. 30, 2016 |
Dec. 31, 2015 |
|||
---|---|---|---|---|---|
Segment Reporting Information [Line Items] | |||||
Property, plant and equipment, net | $ 150,987 | $ 150,218 | [1] | ||
Ireland | |||||
Segment Reporting Information [Line Items] | |||||
Property, plant and equipment, net | 105,892 | 101,736 | |||
Rest Of Europe | |||||
Segment Reporting Information [Line Items] | |||||
Property, plant and equipment, net | 7,117 | 7,334 | |||
United States | |||||
Segment Reporting Information [Line Items] | |||||
Property, plant and equipment, net | 31,750 | 34,520 | |||
Rest of World | |||||
Segment Reporting Information [Line Items] | |||||
Property, plant and equipment, net | $ 6,228 | $ 6,628 | |||
|
Distribution of Depreciation and Amortization by Geographical Area (Detail) - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Jun. 30, 2016 |
Jun. 30, 2015 |
Jun. 30, 2016 |
Jun. 30, 2015 |
|
Segment Reporting Information [Line Items] | ||||
Depreciation and amortization | $ 14,457 | $ 14,244 | $ 29,577 | $ 28,169 |
Ireland | ||||
Segment Reporting Information [Line Items] | ||||
Depreciation and amortization | 6,654 | 4,915 | 12,558 | 9,828 |
Rest Of Europe | ||||
Segment Reporting Information [Line Items] | ||||
Depreciation and amortization | 1,820 | 1,946 | 3,535 | 4,214 |
United States | ||||
Segment Reporting Information [Line Items] | ||||
Depreciation and amortization | 5,137 | 6,417 | 11,786 | 12,135 |
Rest of World | ||||
Segment Reporting Information [Line Items] | ||||
Depreciation and amortization | $ 846 | $ 966 | $ 1,698 | $ 1,992 |
Distribution of Total Assets by Geographical Area (Detail) - USD ($) $ in Thousands |
Jun. 30, 2016 |
Dec. 31, 2015 |
[1] | ||
---|---|---|---|---|---|
Segment Reporting Information [Line Items] | |||||
Assets | $ 1,750,240 | $ 1,717,209 | |||
Ireland | |||||
Segment Reporting Information [Line Items] | |||||
Assets | 620,924 | 663,060 | |||
Rest Of Europe | |||||
Segment Reporting Information [Line Items] | |||||
Assets | 421,570 | 343,733 | |||
United States | |||||
Segment Reporting Information [Line Items] | |||||
Assets | 619,866 | 641,769 | |||
Rest of World | |||||
Segment Reporting Information [Line Items] | |||||
Assets | $ 87,880 | $ 68,647 | |||
|
(('!7R/2QVR9!S@>/P[(LLJRI$?5]:)W :X,7^
M [ NV,CR+'13IK($Z-)+/4P
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MVXW4QQ 7A'F4$K @S<,D6U'5("S9X-9L3==L\.HG,+V@3?DK LC-Q-TEV44:H"P]A]
MD _-SEEXH20&MX*>A1# U52N/"#H20459T.N@PJGAJ8)(
MDD]"2] E1'B=F
MMOII;L_Q%<3%I 05HR 6T&T 749BD*XH7H^8J7.*[T!?,M=!FZ5;I_ZKV"
M$^H.QT%RG_DA),0\'XW],6C+W[NNBT-_"?,"$31;@&Y-$#Y$XX?,"\GS!'DD
MCM'B/!;&[2R<19'Z2W0*\!15(P3J*?A'\221QB2\H^Y+3-(9/'/O/B#^8W('
MKO8\=^(F"9V?#%K7%W.=.(S Q/SS,!H%GI97+ITDD!=4O!R5%"'._/3:/R;
M^=[H"U*CX6:_;RWPN\2N!-B=1N/ H_B,P>TFCWB6&H8SZOM2?W\%KZ@K@^RG
M)%V%F.L]KO?JBVCO".;]IA#8",D47 7J7F0!C^!G)P 8E\[5"$@@]4%F*9Z"
M+$,P9.UT34;FB[@IA*'#63;A-)-<$+:Y FGEVP!W)0N#\I\MLD%Y !1A2+.E
MR.;S:5'KT4-^].4(9D3Q^&=-HA>#V"%0$U="U!&F.--\SCAH&_"/,BVQJOQV
MN3Z+C5+H0W@-H=H$+<$\5YBL1)19\+?021E\P9:/2K.)JUXJ]14!!CQE05=L
M-X8$=Y32'_L$E>[!#%U'WQHLP9G*(
L N4V!CS!F[
M$!@5C:DWHC:[:U!MJM.G678?.W\5%Y1I6T!GHRRC^_>4;#C#5JQUK43]= [O
MG<"'/FJH8"LD>=3QYB+$VH$E!#LL%8G[GF\296M
4NW\!4$L#!!0 ( )1B^DB9
M8GE&8P4 *4; 8 >&PO=V]R:W-H965TV.RVFTOD4VDH B]S>Q"8X$,R;C-XVH38??VI N/!?I4CV\<)"K1[M0IM//6
MS:GN->75?#WJ+M7!U+&O2)H3S$[3G&)VEN8,L_,TYY@]3/,0LT=I'F'V.,UC
MS)ZD>8+9(4AS"- 1D"-HS2"+!K1JD&4#6C?(P@&M'&3I@-8.LGA JP=9/J#U
M@VP H!T V0) >T!D#PC6 _FVR1&L!_*%D2-8#^0:ER-8#^2JE"/C>?9CU2WF
MQV(GOA?M[E!WWEO3RU.Q.A!OFZ87_S<<;@3_FRZ$D#/XAL.J[046ASW=Q-.PFAP9@.7\P7:\T4
MG (*)VVW:[.7?C#X0(O^.N:F65O^!5!+ P04 " "48OI(":+J?V$$ !.
M% &0 'AL+W=O
OX
M+&KS/(^_L-2:S1N -8"K ;QO0*T!]0SB,3)SKL]YEZ\6C3X'[3$?LDWN>G@S
M..D]!_UA6K,TGVO5G1C"[BE\&1@WD8,6 P9 ZQGB* B"LF[B.8#0/<,!Y@
MZF"6PD&0VPS4.R@U]NEX4")O.T@]!ZEQ0.V72F\[8)X#-HV >4]?@=1@PW
M&)D0(>AM'N[Q<(='S/+P"0^D0DJXS2,\'C'ER=@LCYCP? )&>8(@RCRBS#F0
MG"7*ID0IY;=9I, "1&(!)Q90#.+%=3HT!6@U!%QZLSA
MILCF"Y$OTXPLLR+%CQ0_RO!M 60)("6 E$ 2FSEV@Q4#)!F<1 @G+E1IHB!"
M+M1:1\$,)TZMC8%*09S=K@M;=6&MKBA+;@O$ED!\K[.))9#<=G: Q,/7C['3
MLE('H0Q@IZ\Z"$",4Z>O.BI+X8S[EEI%I8:M,P0R2R"[UU80VOTAO&WLB!G]
M2&'H=-9$9
!H;D.$DC4/+!%@%^%\Z5B5U=/Y/KBG8A<7/H#7M*Y! +
MY#S(.2.B%?P']/>9.F9IJH+( \0E%+F)0BY0:*<)S,"W!-@-^;;3)?*H-"E6
M:PZ:'M'B8D0>&*8XW= >C
M$:XM&/AC!@L-] +HW!I]IV!;>U.
FR48^U7G&!?U"U6,_+.JSX]:FIPZHK\N(*%)X!$O)W>@57
M;86*91#.0S'8AV*POTHQV$X"L-SFU8**2I<[TGA[*,;TCUJ,J0=Q;%4)+4%9
M Z927NT^3H#VXCJL6LSHH;C.KUM
QC"GM>)E@8KWRENYE/-3H7J0^<(\[+D"
MR"LN=@R]1D;>,?::$Z9,6[8R%UM59<J-52EY9RB-!CA*EXK
MR:682S'.
"%L"W9%SV6NE4)O//-)[I'\&M),TDV*SITX__,?("Q^-!&%08R)
M$U'X0 "B\$D4/J8N9JMN0+>$HI EU#_3A#@N#BO<@,4G^-4,C#H\^27"+T2A
M^P$7\CWP(E'HQ.X? 3S?C<;19(@_:,=WJ!=#EYYV
MCV'Q+R2>P
#]JHD:17#>
MOM.4 F,?SF@,,%J/>&0R)+&@*6?(; <=RS&NCRN4ADMA^I/G7+# TYPS6!R<
MP0)G<&U7$T_SR1#U,.P\*E7D%RMJ=D29K-[2KF6>1-%8*N^8?SNS4$19'-O'
M"<<4Z>S%3T.:$RBR(=I'=8DY)&]5*X-5